Marcus Autism Centre Discovered First-of-its-kind Early Autism Diagnosis Device

Marcus Autism Centre has discovered first-of-its-kind tool known as EarliPointTM Evaluation, designed to revolutionise the diagnosis of autism in young children.

This innovative technology is authorised for use in children aged between 16 and 30 months, offering a unique approach to the diagnosis and assessment of autism. It is the first of its kind, relying on biomarkers to provide valuable insights into autism.

EarliPointTM Evaluation is capable of collecting data at an astonishing rate of 120 times per second. In just 12 minutes of video observation, it can meticulously analyse a child's moment-by-moment looking behaviour and identify thousands of divergences when compared to typically developing peers.

This tool measures a child's looking behaviour to offer clinicians objective measurements of their strengths and vulnerabilities. The results of recent studies demonstrate its remarkable accuracy in predicting expert clinician assessments.

The ability to provide objective measurements has the potential to significantly reduce the time taken for diagnosis. Furthermore, it expedites the commencement of individualised treatment plans for newly-diagnosed children at a younger age, a practise that has consistently led to improved outcomes for children with autism.

The EarliPoint Evaluation tool holds the promise of altering the course of children's lives by enabling accurate and early diagnosis. It has the potential to empower the healthcare system to address autism more effectively.

Currently, only one in four children with autism is identified before the age of three. EarliPoint Evaluation could play a pivotal role in addressing this significant public health challenge by facilitating earlier diagnoses and initiating treatment interventions.